Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them?

摘要: Thousands of articles describing biomarkers predictive treatment and prognostic survival in cancer have been published, yet only a handful are currently used routinely the clinic. Biomarkers need to be analytically standardized, validated, clinically useful. This review will address challenges ways which we can improve our discovery translation prospective from lab into validated diagnostic tests with specific focus on patients diagnosed glioblastoma MGMT promoter methylation status. There has long-held enthusiasm use as biomarker for treated alkylating agent, temozolomide; however majority centres around world, this not transpired.